Gilead SciencesGILD
Market Cap: $98.1B
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Employees: 18,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
40% more call options, than puts
Call options by funds: $1.02B | Put options by funds: $726M
0% more funds holding in top 10
Funds holding in top 10: 13 [Q1] → 13 (+0) [Q2]
0.41% less ownership
Funds ownership: 83.52% [Q1] → 83.12% (-0.41%) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 626 | Existing positions reduced: 669
3% less funds holding
Funds holding: 1,676 [Q1] → 1,628 (-48) [Q2]
6% less capital invested
Capital invested by funds: $76.2B [Q1] → $71.6B (-$4.56B) [Q2]
27% less first-time investments, than exits
New positions opened: 130 | Existing positions closed: 178
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 6%downside $74 | Sector Perform Maintained | 4 Sept 2024 |
Truist Securities Robyn Karnauskas 43% 1-year accuracy 20 / 47 met price target | 5%upside $83 | Hold Maintained | 15 Aug 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 9%downside $72 | Sector Perform Maintained | 9 Aug 2024 |
Cantor Fitzgerald Olivia Brayer 77% 1-year accuracy 20 / 26 met price target | 11%downside $70 | Neutral Reiterated | 9 Aug 2024 |
BMO Capital Evan Seigerman 69% 1-year accuracy 9 / 13 met price target | 8%upside $85 | Outperform Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 24 articles about GILD published over the past 30 days